initial clinical trials treatment acute myeloid leukemia demonstrated effectiveness alpha emitter 213bi killing cancer cells obtained radionuclide generator decay 225ac parent recent studies shown potential application 213bi 225ac parent radionuclide variety cancer systems targeted radiotherapy paper describes years experience production 225ac partial support clinical trials chemical process consisting anion cation exchange chromatography utilized routine separation 225ac mixture 228th 229th 232th separation ra ac th achieved using marcoporous anion exchange resin mp1 8m hno3 media sequential columns provide separation factor approximately NUMBER ra ac th separation ac ra accomplished low cation exchange resin using 12m hno3 eluant sequential columns provide separation factor approximately NUMBER ac ra processing schedule adopted order reduce processing cost provide highest levels 225ac possible campaign total approximately NUMBER mci 225ac approximately NUMBER theoretical yield shipped batches batch typically consisting approximately NUMBER mci initial separation purification ac ra pool schedule needed provide smaller batches 225ac averaged radioisotopic purity 225ac NUMBER NUMBER 225ra content NUMBER average 229th content x bismuth NUMBER NUMBER days pre clinical going step carrier free cross linking ag50 x4 NUMBER day NUMBER week NUMBER NUMBER processed bi weekly NUMBER NUMBER NUMBER NUMBER mp1 no3 ag50 no3